Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
The consensus estimate for Q3 2024 revenue is $29.84 million, and the earnings are expected to come in at -$0.37 per share. The full year 2024's revenue is expected to be $69 million, and the earnings are expected to be -$1.63 per share. More detailed estimate data can be found on the Forecast page Warning! GuruFocus has detected 4 Warning Sign with RXRX. Over the past 90 days, revenue estimates for Recursion Pharmaceuticals Inc ( NASDAQ:RXRX ) have increased from $58.39 million to $69 million for the full year 2024, and from $81.29 million to $93.31 million for 2025. Similarly, earnings estimates have improved from -$1.65 per share to -$1.63 per share for the full year 2024, and from -$1.83 per share to -$1.79 per share for 2025. In the previous quarter of June 30, 2024, Recursion Pharmaceuticals Inc's ( NASDAQ:RXRX ) actual revenue was $14.42 million, which beat analysts' revenue expectations of $13.26 million by 8.75%. Recursion Pharmaceuticals Inc's ( NASDAQ:RXRX ) actual ea
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Familial Adenomatous Polyposis Pipeline Landscape Report 2024 [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.MarketBeat
- Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryGlobeNewswire
- Recursion and Exscientia Shareholders Approve the Proposed CombinationGlobeNewswire
- Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model GardenGlobeNewswire
RXRX
Earnings
- 11/6/24 - Miss
RXRX
Sec Filings
- 11/21/24 - Form 144
- 11/20/24 - Form 8-K
- 11/20/24 - Form S-8
- RXRX's page on the SEC website